Investigating the possible superiority of early treatment of psoriatic spondyloarthritis (pSpA) patients with biologic treatment as compared to the standard of care.

Delineating the window of opportunity for pSpA: a transient time frame in which a disease is more susceptible to treatment.

Unravelling new biomarkers of therapy response using cutting-edge single-cell technology and epigenetic profiling.

Determining health-economic and societal impact of earlier and more biologic intensive treatment of patients with recent onset pSpA.

Increasing awareness among referring physicians and patient-advocacy groups about the value of early recognition and treatment in rheumatology.